Planned
There are currently no planned studies in our center.
Ongoing
StrateGIST-3 (GSK300383)
A Phase 3 Randomized Multicenter Open-Label Study of IDRX-42 versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : GSK
- More information : NCT07218926
- Indication :
- Internal reference number : s71062
Closed
CABOGIST EORTC 1317
Phase II Study of Cabozantinib in Patients With Gastrointestinal Stromal Tumor (GIST) Who Progressed During Neoadjuvant, Adjuvant or Palliative Therapy With Imatinib and Sunitinib
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : EORTC
- More information : NCT02216578
- Indication :
- Internal reference number : s59545
INTRIGUE DCC-2618-03-002
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : Deciphera Pharmaceuticals LLC
- More information : NCT03673501
- Indication :
- Internal reference number : s62290
INVICTUS DCC2618-03-001
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : Deciphera Pharmaceuticals LLC
- More information : NCT03353753
- Indication :
- Internal reference number : s60897
NAVIGATOR BLU-285-1101
A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : Blueprint
- More information : NCT02508532
- Indication :
- Internal reference number : s58305
VOYAGER BLU-285-1303
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : Blueprint
- More information : NCT03465722
- Indication :
- Internal reference number : s61535